2025
Development of Mouse Models for Ménétrier's Disease.
Gabriel T, Park J, Madala S, Coffey R, Huh W. Development of Mouse Models for Ménétrier's Disease. Journal Of Visualized Experiments 2025 PMID: 40549725, DOI: 10.3791/67981.Peer-Reviewed Original ResearchConceptsSpasmolytic polypeptide-expressing metaplasiaLoss of parietal cellsMouse modelFeatures of MDMouse linesFoveolar hyperplasiaParietal cellsEGF receptorTransforming growth factor-aEGFR-neutralizing antibodyChief cellsDevelopment of mouse modelsChief cell differentiationDecreased acid secretionGiant rugal foldsTransgenic mouse linesInducible mouse modelGrowth factor AModel of MDIn vivo modelsMist1 expressionHistological remissionClinical improvementHistopathological featuresTreatment optionsInsight and Its Trajectory: Predicting the Risk of Psychiatric Hospitalizations Among First-Episode Psychosis During the First Year of Coordinated Specialty Care
Hazan H, Ferrara M, Gibbs-Dean T, Tayfur S, Corbera S, Karmani S, Song Z, Li F, Vlachos I, Selakovic M, Tek C, Srihari V. Insight and Its Trajectory: Predicting the Risk of Psychiatric Hospitalizations Among First-Episode Psychosis During the First Year of Coordinated Specialty Care. Schizophrenia Bulletin 2025, sbaf019. PMID: 40227145, DOI: 10.1093/schbul/sbaf019.Peer-Reviewed Original ResearchCoordinated specialty careFirst-episode psychosisBaseline insightRisk of psychiatric hospitalizationFirst-episodeEarly psychosisInsight groupLength of stayPsychiatric hospitalSpecialty carePsychosisLongitudinal trajectoriesGreater reductionsHospital outcomesHigh-low-highPredicting clinical improvementHospital dataModifiable factorsMonths pre-ParticipantsHospitalization riskClinical improvementRecovery trajectoriesReduce hospitalizationsBaselineAdvancements in minimally invasive interventional oncology procedures for painful sacral metastases under imaging guidance
Jiang W, Gan D, Johnson M, Latich I, Lee F. Advancements in minimally invasive interventional oncology procedures for painful sacral metastases under imaging guidance. EngMedicine 2025, 2: 100051. DOI: 10.1016/j.engmed.2024.100051.Peer-Reviewed Original ResearchPainful sacral metastasesIntra-operative image guidanceSacral metastasesImage guidancePreoperative baselineFollow-upPercutaneous interventionFunction scoresLong-term follow-upRisk of cement leakageO-arm navigationImprovement of painRetrospective cohort reviewImage guidance techniquesAverage follow-upInterventional oncology proceduresIntra-operative imaging techniquesO-armPercutaneous ablationSingle-institutionCohort reviewPrimary cancerClinical improvementMultiple myelomaCement leakageTrauma-Informed Cognitive Behavioral Therapy for Insomnia in Women Veterans: An Intervention Development Study
Carlson G, Kelly M, Erickson A, Saldaña K, Gomez G, Carlson K, Lee D, Pigeon W, McCarthy E, DeViva J, McGowan S, Josephson K, Alessi C, Yano E, Martin J, Hamilton A. Trauma-Informed Cognitive Behavioral Therapy for Insomnia in Women Veterans: An Intervention Development Study. Cognitive And Behavioral Practice 2025 DOI: 10.1016/j.cbpra.2025.03.002.Peer-Reviewed Original ResearchCognitive behavioral therapyCBT-IBehavioral therapyTrauma-related thoughtsTrauma-related symptomsBaseline to 3-month follow-upImprove sleep outcomesIntervention development studyVeterans Affairs providersPTSD treatmentPTSDPsychoeducationWomen veteransSleep outcomesVeteransInsomniaIntervention materialsEngagement groupRandomized clinical trialsDevelopment studiesEvaluation of clinical improvementPsychotherapyClinical improvementInterventionOutcome of development
2024
Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss - A Comorbidity Lens.
Leder Macek A, Wang R, Cottrell J, Kay-Rivest E, McMenomey S, Roland J, Ross F. Hyperbaric Oxygen Therapy for Sudden Sensorineural Hearing Loss - A Comorbidity Lens. Undersea And Hyperbaric Medicine 2024, 51: 393-402. PMID: 39821768, DOI: 10.22462/730.Peer-Reviewed Original ResearchConceptsSudden sensorineural hearing lossSensorineural hearing lossHearing loss onsetHearing lossHyperbaric oxygen therapyWord discrimination scoresSpeech perception outcomesIntratympanic steroid injectionOxygen therapyOral steroid coursesPerception outcomesTone averageSiegel's criteriaClinical improvementPhysician visitsPatient comorbiditiesRheumatologic disordersDiscrimination scoresAssociated with patient outcomesTreated with hyperbaric oxygen therapyCharlson Comorbidity IndexImpact of patient comorbiditiesTertiary referral centerOutcomes of patientsAdjunct to steroidsMOGAD presenting as fulminant intracranial hypertension
Nagaratnam S, Gill A, Jeyakumar N, Xi S, Lin M, Martin A, Varikatt W, Fong M, Morales-Briceno H. MOGAD presenting as fulminant intracranial hypertension. Journal Of Neuroimmunology 2024, 397: 578487. PMID: 39547117, DOI: 10.1016/j.jneuroim.2024.578487.Peer-Reviewed Original ResearchMyelin oligodendrocyte glycoprotein antibody diseaseSevere intracranial hypertensionIntracranial hypertensionFulminant intracranial hypertensionAbsence of demyelinationBrain CT scanManagement of intracranial pressureImmunosuppressive therapyMOG antibodiesBiopsy resultsCortical encephalitisIntensive immunotherapyAntibody diseaseBrainstem encephalitisAntibody positivityClinical improvementSurgical managementNormal MRIBrain biopsyClinical featuresCT scanDifferential diagnosisHypertensionIntracranial pressureSubcortical demyelinationRocky Mountain Spotted Fever Encephalitis and “Starry Sky” Pattern on MRI
Mikhaiel J, Parasram M, Park J, Cappucci S, McGuone D, Falcone G, Sheth K, Gilmore E. Rocky Mountain Spotted Fever Encephalitis and “Starry Sky” Pattern on MRI. The Neurologist 2024, 30: 34-38. PMID: 39382206, DOI: 10.1097/nrl.0000000000000586.Peer-Reviewed Original ResearchMagnetic resonance imagingPetechial rashCase reportDiffusion restrictionMagnetic resonance imaging brainMagnetic resonance imaging brain findingsRepeat MRI brainRocky Mountain spotted feverUrinary tract infectionFoci of diffusion restrictionRight centrum semiovaleProgression to comaPerivascular lymphocytic infiltrateDiffuse petechial rashTract infectionsClinical presentationViral cultureClinical improvementMRI brainLymphocytic infiltrationLumbar punctureSkin biopsiesElevated proteinNeurological manifestationsPunctate fociA Rare Case of Acute Bacterial Native Valve Endocarditis Caused by Streptococcus thoraltensis
Abid S, Stolear A, Dulgher M, Sethi S, Zarich S. A Rare Case of Acute Bacterial Native Valve Endocarditis Caused by Streptococcus thoraltensis. Cureus 2024, 16: e70934. PMID: 39502956, PMCID: PMC11537169, DOI: 10.7759/cureus.70934.Peer-Reviewed Original ResearchNative valve endocarditisIntravenous drug useValve endocarditisRare caseHistory of intravenous drug useLost to follow-upTricuspid valve vegetationPartial clinical improvementDrug useIntravenous ceftriaxoneValve vegetationsBlood culturesChest painPulmonary embolismClinical improvementProductive coughRare pathogenAtrial flutterFollow-upClinical evaluationPatient historyExposure to animalsEndocarditisHuman pathogensPatientsSafety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial
Allen J, Lin J, Basta I, Dysgaard T, Eggers C, Guptill J, Gwathmey K, Hewamadduma C, Hofman E, Hussain Y, Kuwabara S, Le Masson G, Leypoldt F, Chang T, Lipowska M, Lowe M, Lauria G, Querol L, Simu M, Suresh N, Tse A, Ulrichts P, Van Hoorick B, Yamasaki R, Lewis R, van Doorn P, Grinzinger S, Wanschitz J, Seifert-Held T, Claeys K, Baets J, Remiche G, Bissay V, Dubuisson N, Delstanche S, Tarnev I, Genov K, Tsvetanov P, Milanov I, Zhao C, Bu B, Yu X, Li W, Jiang H, Da Y, Lu Z, Liang H, Guo F, Li Z, Zou Z, Hong D, Yang H, Guo J, Shi J, Tu J, He D, Wang Y, Ding J, Zhang Y, Zhao Y, Xu R, Yue Y, Guo A, Wang Y, Talab R, Harbo T, Sindrup S, De Seze J, Sacconi S, Péréon Y, Echaniz-Laguna A, Magy L, Nicolas G, Taithe F, Cassereau J, Debs R, Shakarishvili R, Tsiskaridze A, Mania M, Janelidze M, Janelidze T, Schroeter M, Skripuletz T, Lee D, Klehmet J, Hotter B, Hoffmann O, Baum P, Zschuentzsch J, Pitarokoili K, Stettner M, Bereczki D, Pánczél G, Abraham A, Dori A, Lampl Y, Manganelli F, Morino S, Padovani A, Siciliano G, Schenone A, Magri F, Mazzeo A, Giannini F, Sorbi S, Chiò A, Kuwahara M, Okuno T, Okamoto T, Kokubun N, Nishiyama K, Kaida K, Bokuda K, Katsuno M, Yabe I, Saji E, Yokota T, Hatanaka Y, Nakahara J, Sugimoto T, Tanaka F, Tomita S, Yamano Y, Hayashi T, Yamazaki H, Tokashiki T, Horiuchi K, Karelis G, Eftimov F, Banach M, Chyrchel-Paszkiewicz U, Kochanowicz J, Selmaj K, Zielinski T, Banaszkiewicz K, Mitrea D, Scutaru-Kadar A, Axelerad A, Stuchevskaya F, Boyko A, Khabirov F, Trushnikova T, Goncharova Z, Suponeva N, Dorogov N, Yakupov E, Raicevic R, Miletic Drakulic S, Cabrera Serrano M, Muñoz Blanco J, Guerrero Sola A, Aguera Morales E, Diaz Marin C, Juntas Morales R, Yeh J, Sung J, Huang H, Tsai N, Guo Y, Chao C, Ro L, Sengun I, Terzi M, Alpaydin Baslo S, Koç F, Necdet Karli H, Shulga O, Smolko D, Doroshenko O, Tomakh N, Kyrychenko A, Seliuk O, Kalbus O, Skrypchenko I, Novakovska O, Carod-Artal F, Rinaldi S, Brennan K, Ellis S, Carr A, Matthews E, Traub R, Mozaffar T, Elliott M, Bhavaraju-Sanka R, Nance C, Levine T, Lisak R, Pasnoor M, Pulley M, Roy B, Govindarajan R, Sahagian G, Khella S, Jacob D, Kushlaf H, Sivakumar K, Melamed I, Sharma K, Quick A, Ubogu E, Lacomis D, Isa A, Brannagan T, Chen S, Katz J, Feinberg M, Pavlakis P, Lange D, Gudesblatt M, Tandan R, Gable K, Rivner M, Barnes B, Luke D, Mahuwala Z, Macwan S, Kwon P, Scott J, Altamimi S, Sabharwal P. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology 2024, 23: 1013-1024. PMID: 39304241, DOI: 10.1016/s1474-4422(24)00309-0.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsChronic inflammatory demyelinating polyradiculoneuropathyRisk of relapseInflammatory demyelinating polyradiculoneuropathyStage BStage ADouble-blindModified intention-to-treat populationIntention-to-treat populationOpen-label phaseInflammatory Neuropathy CauseInteractive response technologyPhase 2 trialPlacebo-controlled trialEvidence of clinical improvementClinically meaningful deteriorationPeripheral nervous systemPartial responseSafety populationPlacebo groupPlacebo-controlledResidual neurological impairmentClinical improvementWeeks treatmentTreatment optionsLeveraging real-world data from administrative claims and medical records to inform safety and effectiveness of piperacillin-tazobactam in the management of pediatric hospital–acquired pneumonia
Blumenstock J, Faerber J, Menon M, Lawler R, Downes K, Kratz E, Erickson K, Haltzman-Cassenti B, Yildirim I, Hussaini L, Elmontser M, Sederdahl B, Hahn A, Thomson J, Newland J, Terrill C, Bradley J, Zachariah P, Younus M, Mo J, Wible M, Tawadrous M, Fisher B. Leveraging real-world data from administrative claims and medical records to inform safety and effectiveness of piperacillin-tazobactam in the management of pediatric hospital–acquired pneumonia. American Journal Of Epidemiology 2024, 194: 1426-1435. PMID: 39108170, DOI: 10.1093/aje/kwae251.Peer-Reviewed Original ResearchIncidence rate ratiosPediatric Health Information SystemHospital-acquired pneumoniaMedical recordsHealth information systemsPoisson regression modelsBetween-group differencesStudy combined dataEffects of medicationAdministrative claimsRate ratiosClinical improvementSecondary outcomesBetween-groupEffect of piperacillin-tazobactamComparative riskReal World DataHospital acquired pneumoniaRegression modelsTreating hospital-acquired pneumoniaOff-label settingCIPediatric institutionControlled studiesPiperacillin-tazobactamTranscobalamin receptor antibodies in autoimmune vitamin B12 central deficiency
Pluvinage J, Ngo T, Fouassier C, McDonagh M, Holmes B, Bartley C, Kondapavulur S, Hurabielle C, Bodansky A, Pai V, Hinman S, Aslanpour A, Alvarenga B, Zorn K, Zamecnik C, McCann A, Asencor A, Huynh T, Browne W, Tubati A, Haney M, Douglas V, Louine M, Cree B, Hauser S, Seeley W, Baranzini S, Wells J, Spudich S, Farhadian S, Ramachandran P, Gillum L, Hales C, Zikherman J, Anderson M, Yazdany J, Smith B, Nath A, Suh G, Flanagan E, Green A, Green R, Gelfand J, DeRisi J, Pleasure S, Wilson M. Transcobalamin receptor antibodies in autoimmune vitamin B12 central deficiency. Science Translational Medicine 2024, 16: eadl3758. PMID: 38924428, PMCID: PMC11520464, DOI: 10.1126/scitranslmed.adl3758.Peer-Reviewed Original ResearchConceptsBlood-brain barrierCerebrospinal fluidNeurological deficitsAutoimmune neurological conditionsCohort of patientsCellular uptake of cobalaminVitamin B12B12 transportCerebrospinal fluid samplesMeasurement of vitamin B12Low-density lipoprotein receptorProgrammable phage displayImmunosuppressive treatmentIn vitro modelNeuropsychiatric lupusImmunomodulatory treatmentReceptor antibodiesClinical improvementUptake of cobalaminB12 deficiencyUnknown etiologyHematopoietic cellsTranscobalamin receptorCentral deficiencyB12 supplementationGuselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling
Velasco R, Shao C, Cutler B, Strunck J, Kent G, Cassidy P, Choate K, Greiling T. Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling. JAMA Dermatology 2024, 160: 641-645. PMID: 38598229, PMCID: PMC11007649, DOI: 10.1001/jamadermatol.2024.0257.Peer-Reviewed Original ResearchPsoriasis Area Severity IndexPityriasis rubra pilarisDermatology Life Quality Index scoresInvolvement of interleukinsQuality Index scoreFood and Drug Administration-approved treatmentPrimary outcomeUS Food and Drug Administration-approved treatmentPsoriasis area severity index scoreSex-matched healthy controlsIL-23p19 inhibitorsP19 subunit of IL-23Index scoreArea Severity IndexIL-23/IL-17Subunit of IL-23Per-protocol analysisClinical responseStudy drugDosing scheduleClinical respondersClinical improvementMale patientsIL-23Guselkumab308 Improvement in Cranial Nerve Neuropathies Following Treatment of Intracranial Aneurysms With Flow Diverters: Institutional Outcomes and Meta-analysis of Literature
Sujijantarat N, Antonios J, Koo A, Haynes J, Renedo D, Hebert R, Sheth K, King J, Matouk C. 308 Improvement in Cranial Nerve Neuropathies Following Treatment of Intracranial Aneurysms With Flow Diverters: Institutional Outcomes and Meta-analysis of Literature. Neurosurgery 2024, 70: 89-89. DOI: 10.1227/neu.0000000000002809_308.Peer-Reviewed Original ResearchIntracranial aneurysmsPooled rateMeta-analysisCranial nervesRate of clinical improvementNear total occlusionAneurysms treated with flow diversionCranial nerve neuropathyMonths of presentationFlow diversionAssociated with symptomatic improvementRare presenting symptomSymptomatic intracranial aneurysmsRate of improvementTreatment of intracranial aneurysmsRandom-effects meta-analysisMeta-analysis of literatureEffects meta-analysisOphthalmological outcomesCN deficitsRetrospective reviewAssociated with improvementsClinical improvementNerve neuropathySymptomatic improvement“You can’t really have a relationship with them because they just ask you questions”: understanding adolescent dropout – an empirical single case study
Cirasola A, Szegedi D, Fonagy P, Midgley N. “You can’t really have a relationship with them because they just ask you questions”: understanding adolescent dropout – an empirical single case study. Frontiers In Psychology 2024, 15: 1381901. PMID: 38533210, PMCID: PMC10963658, DOI: 10.3389/fpsyg.2024.1381901.Peer-Reviewed Original ResearchAlliance rupturesPsychoanalytic psychotherapyTherapeutic allianceShort-term psychoanalytic psychotherapyYouth psychotherapyHigh dropout ratesTherapeutic relationshipAdolescent dropoutsPsychotherapyLongitudinal frameworkSingle case studySession recordingsAdolescent engagementParental involvementAdolescent involvementEngaging adolescentsDropout ratesAdolescentsParental engagementTherapistsAllianceSporadic attendanceDropoutClinical improvementDepressionUtility of cortical tissue analysis in normal pressure hydrocephalus
Greenberg A, Mekbib K, Mehta N, Kiziltug E, Duy P, Smith H, Junkkari A, Leinonen V, Hyman B, Chan D, Curry W, Arnold S, Barker F, Frosch M, Kahle K. Utility of cortical tissue analysis in normal pressure hydrocephalus. Cerebral Cortex 2024, 34: bhae001. PMID: 38275188, PMCID: PMC10839843, DOI: 10.1093/cercor/bhae001.Peer-Reviewed Original ResearchConceptsIdiopathic normal pressure hydrocephalus patientsNormal pressure hydrocephalus patientsCerebrospinal fluid shuntsNormal pressure hydrocephalusIdiopathic normal pressure hydrocephalusHydrocephalus patientsPressure hydrocephalusOriginal patient cohortCortical pathologyRisks of treatmentPrognostic adjunctClinical improvementTissue analysisNegative pathologyShunt outcomeClinical outcomesPatient cohortUnfavorable outcomePooled analysisSystematic reviewOriginal cohortPooled statisticsLiving patientsConfounding diagnosesPatients
2023
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi C, Ruddy K, Cathcart-Rake E, Trovato S, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients. Supportive Care In Cancer 2023, 31: 717. PMID: 37991653, DOI: 10.1007/s00520-023-08160-0.Peer-Reviewed Original ResearchConceptsBreast cancer patientsTherapeutic responseAdverse eventsClinical characteristicsCancer patientsCommon cutaneous adverse eventsCutaneous adverse eventsPoor systemic absorptionRetrospective cohort studyComparison of pretreatmentEIA patientsEndocrine monotherapyClinical improvementCohort studyRetrospective cohortOncologic treatmentTopical antiandrogenCombination therapySystemic absorptionAndrogenetic alopeciaDean scaleMethodsThis studyPatientsAlopeciaScore gradeTherapy for Chikungunya Arthritis: A Study of 133 Brazilian Patients.
Amaral J, Bingham C, Taylor P, Vilá L, Weinblatt M, Schoen R. Therapy for Chikungunya Arthritis: A Study of 133 Brazilian Patients. American Journal Of Tropical Medicine And Hygiene 2023, 109: 542-547. PMID: 37549898, PMCID: PMC10484246, DOI: 10.4269/ajtmh.23-0205.Peer-Reviewed Original ResearchConceptsChikungunya arthritisWeeks of treatmentSwollen joint countTender joint countJoint countDAS28-erythrocyte sedimentation rateAge of patientsTreated with methotrexateDisease Activity ScoreGroup of patientsMedical record reviewAcute chikungunyaPain scoresClinical improvementBrazilian patientsAssess painClinical criteriaBaseline visitActivity scoreMaintained 5 monthsPainPatientsRecord reviewSelf-limitingRheumatology practiceRetrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.
Minta A, Rose L, Park C, Trovato S, Lustberg M, Sudheendra P, Cherian M, Gatti-Mays M, Stover D, Wesolowski R, Sardesai S, Ramaswamy B, Williams N, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer. Journal Of Clinical Oncology 2023, 41: e13083-e13083. DOI: 10.1200/jco.2023.41.16_suppl.e13083.Peer-Reviewed Original ResearchBreast cancerEIA patientsDermatology referralsOnset of alopeciaRetrospective cohort studyMetastatic breast cancerRisk of alopeciaCyclin-dependent kinase 4Endocrine monotherapyOral minoxidilEndocrine therapyClinical improvementCohort studyRetrospective cohortFemale patientsTherapeutic optionsCombination therapyGrade severityTherapeutic responseFavorable outcomeAndrogenetic alopeciaDean scaleCDK4/6iPatientsSignificant improvementGamma knife capsulotomy for intractable OCD: Neuroimage analysis of lesion size, location, and clinical response
McLaughlin N, Magnotti J, Banks G, Nanda P, Hoexter M, Lopes A, Batistuzzo M, Asaad W, Stewart C, Paulo D, Noren G, Greenberg B, Malloy P, Salloway S, Correia S, Pathak Y, Sheehan J, Marsland R, Gorgulho A, De Salles A, Miguel E, Rasmussen S, Sheth S. Gamma knife capsulotomy for intractable OCD: Neuroimage analysis of lesion size, location, and clinical response. Translational Psychiatry 2023, 13: 134. PMID: 37185805, PMCID: PMC10130137, DOI: 10.1038/s41398-023-02425-2.Peer-Reviewed Original ResearchConceptsY-BOCS reductionObsessive-compulsive disorderGamma knife capsulotomyLesion sizeRefractory obsessive-compulsive disorderOverall lesion volumeIntractable obsessive-compulsive disorderLesion-symptom mappingVoxel-wise lesion-symptom mappingClinical improvementClinical responseWhite matter pathwaysClinical outcomesFull respondersConventional therapyInternal capsuleLesion characteristicsLesion volumeAnterior limbEffective treatmentLesion locationLesion occurrenceCoronal planeSize/locationPatientsPsilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Sloshower J, Skosnik P, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal Of Psychopharmacology 2023, 37: 698-706. PMID: 36938991, DOI: 10.1177/02698811231154852.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAntidepressant effectsDepressive disorderSevere major depressive disorderPsilocybin-assisted therapyEarly phase studiesQuality of lifeClinical improvementDosing sessionsMajor depressionPsilocybin administrationPlacebo effectPsychotherapeutic supportPlaceboTherapy effectsStudy periodPsychotherapy studiesFurther studiesSignificant differencesDepressionDosingTherapyHigh rateEffect sizeDegree of change
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply